With its annual essay competition, the Alzheimer’s Foundation of America (AFA) is again offering high schoolers affected by Alzheimer’s disease a chance to motivate others and earn money for college. In the AFA Teens for Alzheimer’s Awareness College Scholarship Essay Contest, college-bound high school seniors nationwide are invited…
[Editor’s note: This story, published on Dec. 10, was updated on Dec. 16 with additional details provided by Acadia Pharmaceuticals.] People with Alzheimer’s and other dementias treated with Nuplazid (pimavanserin) in a Phase…
A recent Phase 1 clinical study of a potential Alzheimer’s therapy showed positive results regarding both safety and biomarkers for cognitive processes. The data support advancing the investigational compound, NDX-1017, developed by Athira Pharma, to later-stage clinical trials. The results, “Phase 1 Study of NDX-1017: Safety, Pharmacokinetics…
Researchers at Maastricht University Medical Center in the Netherlands have developed two online apps to improve the lives of people who care for dementia patients, and will soon create one for patients themselves. One app provides caregivers with information they can use to achieve balance in their lives. Those participating in…
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a second round of research awards totaling about $6 million, part of its Diagnostics Accelerator initiative into better diagnostics for Alzheimer’s (AD) and related dementia. These six global investigative efforts are in various stages of development, and include an advanced blood…
Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene” was…
INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead…
A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development…
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow…
Get regular updates to your inbox.